CN1298708C - 1-(2,6-二氟苄基)-1h-1,2,3-三唑-4-甲酰胺的结晶改良体及其用途 - Google Patents
1-(2,6-二氟苄基)-1h-1,2,3-三唑-4-甲酰胺的结晶改良体及其用途 Download PDFInfo
- Publication number
- CN1298708C CN1298708C CNB2004100473675A CN200410047367A CN1298708C CN 1298708 C CN1298708 C CN 1298708C CN B2004100473675 A CNB2004100473675 A CN B2004100473675A CN 200410047367 A CN200410047367 A CN 200410047367A CN 1298708 C CN1298708 C CN 1298708C
- Authority
- CN
- China
- Prior art keywords
- modification
- difluorobenzyl
- triazole
- methane amide
- little less
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000012986 modification Methods 0.000 title claims abstract description 91
- 230000004048 modification Effects 0.000 title claims abstract description 91
- 206010015037 epilepsy Diseases 0.000 title claims abstract description 6
- 239000013078 crystal Substances 0.000 title abstract description 14
- POGQSBRIGCQNEG-UHFFFAOYSA-N rufinamide Chemical compound N1=NC(C(=O)N)=CN1CC1=C(F)C=CC=C1F POGQSBRIGCQNEG-UHFFFAOYSA-N 0.000 title abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 8
- 150000001875 compounds Chemical class 0.000 claims abstract description 5
- 238000001228 spectrum Methods 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 10
- 230000003595 spectral effect Effects 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 8
- 238000005079 FT-Raman Methods 0.000 claims description 5
- 238000010521 absorption reaction Methods 0.000 claims description 4
- 238000001028 reflection method Methods 0.000 claims description 4
- 238000001938 differential scanning calorimetry curve Methods 0.000 claims description 3
- 238000002329 infrared spectrum Methods 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000001237 Raman spectrum Methods 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000001157 Fourier transform infrared spectrum Methods 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 238000001953 recrystallisation Methods 0.000 description 4
- 238000001757 thermogravimetry curve Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000001961 anticonvulsive agent Substances 0.000 description 3
- 229960003965 antiepileptics Drugs 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 125000006850 spacer group Chemical group 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 125000006508 2,6-difluorobenzyl group Chemical group [H]C1=C([H])C(F)=C(C(F)=C1[H])C([H])([H])* 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920003084 Avicel® PH-102 Polymers 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- RCEAADKTGXTDOA-UHFFFAOYSA-N OS(O)(=O)=O.CCCCCCCCCCCC[Na] Chemical compound OS(O)(=O)=O.CCCCCCCCCCCC[Na] RCEAADKTGXTDOA-UHFFFAOYSA-N 0.000 description 1
- 101150064233 Pan2 gene Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 238000001069 Raman spectroscopy Methods 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000020245 homoiothermy Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- -1 polyoxyethylene Polymers 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 208000037921 secondary disease Diseases 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 230000005477 standard model Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 238000012982 x-ray structure analysis Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
Abstract
本发明涉及新的式(I)所示的化合物1-(2,6-二氟苄基)-1H-1,2,3-三唑-4-甲酰胺的改良体C,它治疗癫痫的用途以及含有这些结晶改良体的药物制剂。
Description
酰胺的结晶改良体及其用途
本申请是申请号为98805675.5、申请日为1998年6月8日、发明名称为“1-(2,6-二氟苄基)-1H-1,2,3-三唑-4-甲酰胺的结晶改良体及其用作抗癫痫药的用途”的中国专利申请的分案申请。
技术领域
本发明涉及1-(2,6-二氟苄基)-1H-1,2,3-三唑-4-甲酰胺的结晶改良体及其用作抗癫痫药的用途。
背景技术
下式所示的化合物1-(2,6-二氟苄基)-1H-1,2,3-三唑-4-甲酰胺:
已在欧洲专利申请公开No.0 199 262 A2(EP 199262)中有所描述,例如实施例4。该化合物显示出有价值的药理学特性;因此可将它用作例如抗癫痫药。化合物1-(2,6-二氟苄基)-1H-1,2,3-三唑-4-甲酰胺是按照EP199262中的方法、以2,6-二氟苄基叠氮化物为起始反应物并通过形成1-(2,6-二氟苄基)-1H-1,2,3-三唑-4-羧酸而制得,该方法类似于实施例2。
EP199262中没有记载任何关于获得可能的结晶改良体的内容。若按照实施例4所述的方法并结合实施例2,制备的1-(2,6-二氟苄基)-1H-1,2,3-三唑-4-甲酰胺粗产物最终是以乙醇重结晶。然而,EP199262中并未明确这种重结晶是要特别采用或需在特定条件下进行。现惊奇地发现,通过对具体选择的反应条件进行选择,例如选择适宜的重结晶溶剂和重结晶时间,可制备特征如下的不同结晶改良体(同质多晶)。
发明内容
所得1-(2,6-二氟苄基)-1H-1,2,3-三唑-4-甲酰胺可以新的结晶改良体-A、A’、B和C形式获得。这些结晶改良体的区别在于:它们的热力学稳定性、如IR和拉曼光谱吸收图谱等物理学参数、X-射线结构分析以及它们的制备方法。
本发明涉及新的B和C结晶改良体、它们的制备方法以及在含有该结晶改良体的药物制剂中的应用。
与A相比,改良体A’在其晶格中有缺陷。这可通过例如X-射线分析的方法对它们进行测定,例如通过对谱线间距的减小以及其他基本相同的谱线或谱带进行分析。
1-(2,6-二氟苄基)-1H-1,2,3-三唑-4-甲酰胺的新结晶改良体A在242℃(239-245℃)下熔化。
在FT红外(FT-IR)光谱(KBr压片-透射法)中,改良体A或A’在许多谱带的形状和相对强度上与改良体B和C明显不同。其特有的在改良体B和C的FT-IR光谱中不曾存在的特征是:3412cm-1和3092cm-1处的谱带[参见:附图1]。在4000-600cm-1范围内,由改良体A测得下列特征谱带:3412、3189、3092、1634、1560、1473、1397、1325、1300、1284、1235、1125、1053、1036、1014、885、840、799、781、723、688和640cm-1。可使用例如IFS 88(Bruker)仪器来记录各改良体的FT-IR光谱。
在FT拉曼光谱(粉末-反射法180°)中,改良体A或A’在许多谱带的形状和相对强度上与改良体B和C明显不同。其特有的在改良体B和C的拉曼光谱中不曾存在的特征是:1080cm-1处的谱带[参见:附图2]。在3400-300cm-1范围内,由改良体A测得下列特征谱带:3093、2972、1628、1614、1558、1465、1446、1393、1279、1245、1147、1080、1061、1036、1014、840、724、691、667、550、499、437和368cm-1。可使用例如RFS 100(Bruker)仪器来记录各改良体的FT拉曼光谱。
新改良体A在其X-射线粉末图谱中具有面间距(d值)为:10.5,5.14,4.84,4.55,4.34,4.07,3.51,3.48,3.25,3.19,3.15,3.07,2.81的特征谱线[参见附表1]。该测量可以以例如透射几何学的方式、使用由Enraf-Nonius,Delft(荷兰)生产的FR 552纪尼叶照相机并利用铜Kα1射线(波长=1.54060)来完成。记录在X-射线胶片上的图谱可用Johannsson,Taby(瑞典)生产的LS-18线性扫描器进行测量并用Scanpi软件(P.E.Werner,Stockholm大学)进行计算。
新改良体A的特征在于其由差示扫描量热法测得的热分析图。在该图的230-260℃范围间显示一个吸热峰。该峰值温度为239-245℃并且该吸热信号为209J/g+/-10J/g。测量是利用Perkin Elmer DSC 7、在一个封闭盘内并以20K/分钟的加热速度来完成。标准样品量约为4mg。作为不同于改良体B和C的典型区别特征是:改良体A的热分析图中没有其他热信号。
改良体A’的结晶具有与改良体A相同的晶体结构。但它与改良体A在X一射线粉末图谱中的区别是:其特征谱线对之间的线间距微微减小。它们是具有下列面间距的谱线对:3.68和3.64、3.51和3.48、3.19和3.15。
在FT-IR(KBr压片-透射法)光谱中,改良体B在许多谱带的形状和相对强度上与改良体A、A’和C明显不同,其特征在于1678cm-1处的谱带[参见:附图1],这在改良体A和C的相应图谱中未发现。在4000-600cm-1之间,由改良体B获得下列特征谱带:3404,3199,3125,1678,1635,1560,1475,1393,1357,1322,1286,1237,1051,1036,1028,889,837,800,719,667和645cm-1.。可使用如IFS 85(Bruker)仪来记录各改良体的FT-IR光谱。
在FT-拉曼光谱(粉末-反射法180°)中,改良体B在许多谱带的形状和相对强度上与改良体A、A′和C明显不同,其特征在于3166cm-1和1086cm-1处的谱带[参见:附图2],这在改良体A和C的拉曼图谱中并不存在。在3400-300cm-1之间,由改良体B获得下列特征谱带:3166,3089,2970,1678,1628,1614,1559,1464,1441,1391,1275,1244,1147,108
6,1062,1036,1014,839,773,724,690,668,595,549,500,493,430和365cm-1.
可使用如RFS 100(Bruker)仪来记录各改良体的FT-拉曼光谱。
改良体B在其X-射线粉末图谱中具有面间距(d值)为:11.0,8.3,5.18,4.88,4.80,4.42,4.33,4.19,4.12,3.81,3.50,3.41,3.36,3.32,3.28,3.24,3.05,2.83的特征谱线[参见:附表1]。
在差示扫描量热法测得的热分析图中,改良体B除在230-260℃范围内有一个吸热信号(峰值温度239-245℃)外,在205℃(180-220℃)处还有一个弱的热信号并且该信号成为不同于改良体A或A’和C的典型区别特征。
在FT-IR(KBr压片-透射法)光谱中,改良体C在许多谱带的形状和相对强度上与改良体A、A’和B明显不同。其特征在于3137cm-1处的谱带[参见:附图1],这在改良体A和B的相应图谱中并未发现。
在4000-600cm-1之间,由改良体C获得下列特征谱带:C:3396,3287,3137,1657,1631,1602,1559,1475,1392,1323,1287,1237,1122,1104,1047,1035,1012,876,839,797,773,729和653cm-1.可使用如IFS 85(Bruker)仪器来记录各改良体的FT-IR光谱。
在FT-拉曼光谱(粉末-反射法180°)中,改良体C在许多谱带的形状和相对强度上与改良体A或A’和B明显不同。其特有的在改良体A和B的拉曼光谱中不曾存在的特征是:3137和1602cm-1处的谱带[参见:附图2]。在3400-300cm-1之间,由改良体C获得下列特征谱带:3137,3080,3012,2971,1673,1629,1602,1561,1436,1271,1248,1105,1065,1035,1013,839,800,767,726,690,672,593,549,500,492,435和370cm-1。可使用例如RFS100(Bruker)仪来记录各改良体的FT拉曼光谱。
改良体C在其X-射线粉末图谱中具有面间距(d值)为:9.0,4.73,4.65,3.75,3.54,3.42,3.25的特征谱线[参见附表1]。在差示扫描量热法测得的热分析图中,改良体C除在230-260℃范围内有一个吸热信号(峰值温度为239-245℃)外,其在180℃区域内还有一个不同于改良体A或A’和B的很宽并较弱的放热信号。
表1:改良体A、B和C(X-射线粉末图谱)的特征
改良体A: | 改良体B: | 改良体C: | |||
d[] | 强度 | d[] | 强度 | d[] | 强度 |
10.9 | 弱 | 11.0 | 中等 | 9.0 | 中等 |
10.5 | 中等 | 8.3 | 中等 | 7.0 | 弱 |
6.6 | 弱 | 8.1 | 很弱 | 5.49 | 弱 |
5.63 | 弱 | 5.68 | 很弱 | 5.11 | 很弱 |
5.25 | 弱 | 5.18 | 很强 | 4.80 | 弱 |
5.14 | 中等 | 5.11 | 弱 | 4.73 | 强 |
4.94 | 弱 | 4.88 | 中等 | 4.65 | 很强 |
4.84 | 很强 | 4.80 | 强 | 4.47 | 很弱 |
4.55 | 强 | 4.71 | 很弱 | 4.19 | 很弱 |
4.42 | 很弱 | 4.61 | 弱 | 4.11 | 很弱 |
4.34 | 中等 | 4.45 | 弱 | 3.98 | 很弱 |
4.23 | 很弱 | 4.42 | 强 | 3.83 | 很弱 |
4.16 | 弱 | 4.33 | 很强 | 3.75 | 强 |
4.07 | 中等 | 4.19 | 中等 | 3.73 | 弱 |
4.01 | 弱 | 4.12 | 强 | 3.54 | 中等 |
3.68 | 很弱 | 4.09 | 弱 | 3.50 | 弱 |
3.64 | 很弱 | 3.99 | 很弱 | 3.42 | 强 |
3.60 | 弱 | 3.95 | 很弱 | 3.25 | 中等 |
3.56 | 弱 | 3.84 | 弱 | 2.88 | 很弱 |
3.51 | 中等 | 3.81 | 中等 | 2.80 | 很弱 |
3.48 | 中等 | 3.65 | 弱 | 2.74 | 很弱 |
3.38 | 很弱 | 3.61 | 很弱 | 2.67 | 很弱 |
3.25 | 强 | 3.58 | 很弱 | 2.64 | 弱 |
3.19 | 中等 | 3.54 | 弱 |
3.15 | 中等 | 3.50 | 中等 | ||
3.11 | 弱 | 3.47 | 很弱 | ||
3.07 | 中等 | 3.41 | 中等 | ||
2.93 | 很弱 | 3.36 | 很强 | ||
2.87 | 很弱 | 3.32 | 强 | ||
2.81 | 中等 | 3.28 | 中等 | ||
2.76 | 弱 | 3.24 | 中等 | ||
2.73 | 很弱 | 3.10 | 弱 | ||
2.68 | 弱 | 3.07 | 弱 | ||
2.62 | 很弱 | 3.05 | 中等 | ||
2.53 | 弱 | 2.93 | 弱 | ||
2.43 | 弱 | 2.88 | 弱 | ||
2.40 | 很弱 | 2.87 | 很弱 | ||
2.83 | 中等 | ||||
2.66 | 弱 | ||||
2.63 | 很弱 | ||||
2.55 | 弱 | ||||
2.50 | 弱 | ||||
2.46 | 弱 | ||||
2.44 | 弱 | ||||
2.37 | 弱 | ||||
2.35 | 弱 |
单晶X-射线分析:
改良体A、B和C的晶体质量和单位晶胞将通过韦森堡和徘循照相进行鉴定。用四轴Nonius CAD-4衍射仪测量强度。用SHELXS-97解析晶体结构并以SHELXL-97软件进行精确化。
改良体A
空间群:Pan21-斜方晶的
晶胞大小:
a=24.756(5) b=23.069(4) c=5.386(1)
v=3075.93 Z=12 Dx=1.543gcm-3
V/分子式: Vz=256.33
9011个特征反射;其中有2479个反射具有I>2σ(I)的显著性。精确了557个参数。
通过差示傅里叶图确定并按各向同性方式精算出所有H原子的位置。可靠性指数R1:3.65%(所有9011反射的wR2:11.34%)。
改良体B
空间群:P-1-三斜晶的
晶胞大小:
a=5.326(1) b=11.976(2) c=17.355(3)
α=107.22(3)° β=92.17(3)° γ=102.11(3)°
v=1027.93 Z=4 Dx=1.539gcm-3
V/分子式 Vz=257.03
4934个特征反射;其中有834个具有I>2σ(I)的显著性。精确了232个参数。
通过差示傅里叶图确定并按各向同性方式精算出所有H原子的位置。
可靠性指数R1:4.20%(所有4934反射的wR2:7.93%)
改良体C
空间群:P21/C-单斜晶的
晶胞大小:
a=10.982(2) b=5.350(1) c=17.945(3)
β=91.59(1)°
v=1053.93 Z=4 Dx=1.501gcm-3
V/分子式: Vz=263.53
3073个特征反射;其中有1071个具有I>2σ(I)的显著性。精确了187个参数。
通过差示傅里叶图确定并按各向同性方式精算出所有H原子位置。可靠性指数R1:5.02%(所有3073反射的wR2:14.55%)
与改良体A或A’相比,改良体B和C具有有价值的药理学特性;尤其可将它们用于癫痫的治疗。
与改良A或A’相比,改良体B和C具有突出的优越性。
我们发现,例如,改良体B与改良体A或A’相比在水和胃液中的溶解速率较快。因此改良体B用于治疗时可以达到快速起作用的效果,这一点对于如急性癫痫发作是特别有利的。
本发明涉及1-(2,6-二氟苄基)-1H-1,2,3-三唑-4-甲酰胺的改良体B,其特征在于其在红外图谱(KBr压片-透射法)中具有下列吸收:1678cm-1谱带。
本发明涉及1-(2,6-二氟苄基)-1H-1,2,3-三唑-4-甲酰胺的改良体B,其特征在于:由X-射线粉末图谱法测定的具有11.0,8.3,5.18,4.88,4.80,4.42,4.33,4.19,4.12,3.81,3.50,3.41,3.36,3.32,3.28,3.24,3.05和2.83,面间距(d值)的特征谱线。
本发明涉及1-(2,6-二氟苄基)-1H-1,2,3-三唑-4-甲酰胺的改良体B,其特征在于具有如表1所示面间距(d值)的特征谱线。
本发明涉及1-(2,6-二氟苄基)-1H-1,2,3-三唑-4-甲酰胺的改良体B,它在差示扫描量热法热分析图中除在230-260℃范围内有一个吸热信号(峰值温度239-245℃)外,在205℃(180-220℃)处还有一个弱的热信号。
本发明涉及1-(2,6-二氟苄基)-1H,-1’2,3-三唑-4-甲酰胺的改良体C,它在红外图谱(KB1压片-透射法)中具有下列吸收:3137cm-1谱带。
本发明涉及1-(2,6-二氟苄基)-1H,-1,2,3-三唑-4-甲酰胺的改良体C,,其特征在于其X-射线粉末图谱中具有面间距(d值)为:9.0,4.73,4.65,3.75,3.54,3.42,3.25。
本发明涉及1-(2,6-二氟苄基)-1H,-1,2,3-三唑-4-甲酰胺的改良体C,其特征在于具有如表1所示面间距(d值)的特征谱线。
本发明涉及1-(2,6-二氟苄基)-1H,-1,2,3-三唑-4-甲酰胺的改良体C,它在差示扫描量热法热分析图中除在230-260℃范围内有一个吸热信号(峰值温度239-249℃)外,在180℃区域内还有一个很宽并较弱的放热信号。
本发明涉及1-(2,6-二氟苄基)-1H-1,2,3-三唑-4-甲酰胺的基本纯的改良体B和C。术语“基本纯”是指以改良体B和C计的纯度>95%,优选>98%,最佳>99%。
本发明涉及含有1-(2,6-二氟苄基)-1H-1,2,3-三唑-4-甲酰胺改良体B和C的药物制剂。本发明特别涉及适于治疗癫痫及其继发病症的药物制剂。本发明还涉及1-(2,6-二氟苄基)-1H-1,2,3-三唑-4-甲酰胺改良体B和C在制备药物制剂中的应用,尤其是在制备治疗癫痫及其继发病症药物制剂中的应用。
新的1-(2,6-二氟苄基)-1H-1,2,3-三唑-4-甲酰胺改良体B和C可以以例如含有有效治疗量活性组分的药物制剂形式来使用,如果需要可结合无机或有机的、固体或液体的、适宜肠胃内(如口服)或肠胃外给药的可药用载体。此外,新的1-(2,6-二氟苄基)-1H-1,2,3-三唑-4-甲酰胺改良体B和C可以采用肠胃外给药或输注溶液的制剂形式给药。上述药物制剂可以经灭菌处理和/或包含例如防腐剂、稳定剂、湿润剂和/或乳化剂、增溶剂、渗透压调节用盐和/或缓冲剂的赋形剂。本发明药物制剂含有约0.1-100%、优选约1-50%的冻干品至约100%的活性组分。
本发明还涉及1-(2,6-二氟苄基)-1H-1,2,3-三唑-4-甲酰胺改良体B和C的用途,尤其是在药物制剂中的用途。所用剂量将取决于多种因素,例如给药方式、物种、患者年龄和/或个体状况。口服给药情况下的每日给药剂量介于约0.25-10mg/kg,并且对于体重约为70Kg的温血物种而言优选介于约20-50mg范围内。
附图说明
附图1是结晶改良体A、B和C的KBr压片的FT-IR光谱图示。
附图2是改良体A、B和C的粉末的FT-拉曼光谱图示。
在两个附图中,改良体A用符号*表示,改良体B用符号**表示而改良体C以符号***表示。
具体实施方式
改良体B和C的制备可通过例如下列实施方式来完成。
实施例1:改良体B
在搅拌和58-63℃下将1-(2,6-二氟苄基)-1H-1,2,3-三唑-4-甲酰胺(18.29kg)溶解在甲酸(89.3kg)中。将上述溶液在20℃至0℃下、以30分钟的时间加入到搅拌的甲醇(105.5升)中然后用甲酸(6.1kg)洗涤,以形成一悬浮液。产物经过滤立即得以分离,用冷甲醇(150升,约4℃)洗涤。于约60℃真空干燥,得到产物改良体B,产率约为94%。
实施例2:改良体C
在搅拌和约90℃下将1-(2,6-二氟苄基)-1H-1,2,3-三唑-4-甲酰胺(15.0g)溶于乙酸(120ml)中。在约8分钟期间内将溶液冷却至20℃,形成悬浮液。产物经过滤立即得以分离,用甲苯(120ml)洗涤,于约60℃真空干燥。得到产物改良体C。产率67.3%。
制剂实施例1:
每剂量单位分别含有100、200或400mg的1-(2,6-二氟苄基)-1H-1,2,3-三唑-4-甲酰胺改良体B或C和下列组分的膜包衣片剂:
芯材 | mg | mg | mg |
活性组分无水、胶体二氧化硅微晶纤维素羟丙基甲基纤维素乳糖硬脂酸镁玉米淀粉羧甲基纤维素钠十二烷基硫酸钠 | 100.000.8836.625.0020.002.0010.005.000.50 | 200.001.7573.2510.0040.004.0020.0010.001.00 | 400.003.5146.5020.0080.008.0040.0020.002.00 |
包衣膜 | mg | mg | mg |
羟丙基甲基纤维素红氧化铁聚乙二醇8000絮片体滑石二氧化钛 | 3.220.040.582.330.83 | 6.430.091.164.661.66 | 12.870.182.329.313.32 |
将活性组分和去离子水一起制粒。然后将研碎的乳糖、玉米淀粉、Avicel PH 102、纤维素-HP-M-603和十二烷基硫酸钠加入到上述混合物中并与去离子水进一步制粒。
将所得湿材干燥并磨碎。加入其余组分后将匀质的混合物压制以制得具有上述活性组分含量的片剂内芯。
将片剂内芯用由适宜组分组成的包膜物进行包衣,后者是溶解或悬浮于水或少量含有5%异丙醇的乙醇中。
Claims (5)
1.下列化合物1-(2,6-二氟苄基)-1H-1,2,3-三唑-4-甲酰胺的改良体C,
其特征在于:
-以X-射线粉末图谱方法测定的面间距d值为9.0、4.73、4.65、3.75、3.54、3.42、3.25;
-KBr压片-透射法测定红外光谱具有下列吸收:3396,3287,3137,1657,1631,1602,1559,1475,1392,1323,1287,1237,1122,1104,1047,1035,1012,876,839,797,773,729和653cm-1;
-粉末-反射法180°测定FT-拉曼光谱具有下列吸收:3137,3080,3012,2971,1673,1629,1602,1561,1436,1271,1248,1105,1065,1035,1013,839,800,767,726,690,672,593,549,500,492,435和370cm-1;
-它在差示扫描量热法热分析图中除在230-260℃范围内有吸热信号外,峰值温度239-245℃,在180℃区域有一很宽的弱放热信号。
2.权利要求1中的改良体C,其特征在于X-射线粉末图谱具有下列面间距d值特征谱线:9.0,7.0,5.49,5.11,4.80,4.73,4.65,4.47,4.19,4.11,3.98,3.83,3.75,3.73,3.54,3.50,3.42,3.25,2.88,2.80,2.74,2.67,2.64。
3.权利要求1或2的改良体C,其纯度大于95%。
4.药物制剂,该制剂含有权利要求1或2的1-(2,6-二氟苄基)-1H-1,2,3-三唑-4-甲酰胺改良体C以及可药用赋形剂和添加剂。
5.权利要求1或2的1-(2,6-二氟苄基)-1H-1,2,3-三唑-4-甲酰胺改良体C用于制备治疗癫痫及其继发病症的药物制剂的用途。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH140497 | 1997-06-10 | ||
CH1404/97 | 1997-06-10 | ||
CH1404/1997 | 1997-06-10 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB988056755A Division CN1159300C (zh) | 1997-06-10 | 1998-06-08 | 1-(2,6-二氟苄基)-1h-1,2,3-三唑-4-甲酰胺的结晶改良体及其用作抗癫痫药的用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1572789A CN1572789A (zh) | 2005-02-02 |
CN1298708C true CN1298708C (zh) | 2007-02-07 |
Family
ID=4209650
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB988056755A Expired - Lifetime CN1159300C (zh) | 1997-06-10 | 1998-06-08 | 1-(2,6-二氟苄基)-1h-1,2,3-三唑-4-甲酰胺的结晶改良体及其用作抗癫痫药的用途 |
CN988000113A Expired - Lifetime CN1132820C (zh) | 1997-06-10 | 1998-06-08 | 药物的结晶改良体 |
CNB2004100473675A Expired - Lifetime CN1298708C (zh) | 1997-06-10 | 1998-06-08 | 1-(2,6-二氟苄基)-1h-1,2,3-三唑-4-甲酰胺的结晶改良体及其用途 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB988056755A Expired - Lifetime CN1159300C (zh) | 1997-06-10 | 1998-06-08 | 1-(2,6-二氟苄基)-1h-1,2,3-三唑-4-甲酰胺的结晶改良体及其用作抗癫痫药的用途 |
CN988000113A Expired - Lifetime CN1132820C (zh) | 1997-06-10 | 1998-06-08 | 药物的结晶改良体 |
Country Status (37)
Country | Link |
---|---|
US (6) | US6740669B1 (zh) |
EP (2) | EP0994864B1 (zh) |
JP (2) | JP3672574B2 (zh) |
KR (2) | KR100425656B1 (zh) |
CN (3) | CN1159300C (zh) |
AR (4) | AR012945A1 (zh) |
AT (2) | ATE237599T1 (zh) |
AU (2) | AU725528B2 (zh) |
BR (2) | BR9804946A (zh) |
CA (3) | CA2256013C (zh) |
CO (2) | CO4940452A1 (zh) |
CY (1) | CY2007014I2 (zh) |
CZ (2) | CZ292260B6 (zh) |
DE (3) | DE69811500T2 (zh) |
DK (2) | DK0994864T3 (zh) |
ES (2) | ES2192779T3 (zh) |
FR (1) | FR07C0037I2 (zh) |
HK (3) | HK1028241A1 (zh) |
HU (2) | HU225153B1 (zh) |
ID (2) | ID21014A (zh) |
IL (2) | IL125732A (zh) |
LU (1) | LU91345I2 (zh) |
MY (2) | MY125854A (zh) |
NL (1) | NL300284I2 (zh) |
NO (2) | NO329315B1 (zh) |
NZ (2) | NZ331371A (zh) |
PE (2) | PE80999A1 (zh) |
PL (2) | PL192114B1 (zh) |
PT (1) | PT994864E (zh) |
RU (2) | RU2194041C2 (zh) |
SI (2) | SI0994863T1 (zh) |
SK (2) | SK283685B6 (zh) |
TR (2) | TR199801631T1 (zh) |
TW (2) | TW526195B (zh) |
UY (1) | UY25844A1 (zh) |
WO (2) | WO1998056772A1 (zh) |
ZA (2) | ZA984967B (zh) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW526195B (en) * | 1997-06-10 | 2003-04-01 | Novartis Ag | Crystal modifications of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and their use |
ATE390425T1 (de) * | 2002-05-31 | 2008-04-15 | Schering Corp | Xanthin-phosphodiesterase-v-hemmer polymorphe |
GB0507298D0 (en) | 2005-04-11 | 2005-05-18 | Novartis Ag | Organic compounds |
US7875284B2 (en) * | 2006-03-10 | 2011-01-25 | Cook Incorporated | Methods of manufacturing and modifying taxane coatings for implantable medical devices |
US20090069390A1 (en) * | 2007-09-12 | 2009-03-12 | Protia, Llc | Deuterium-enriched rufinamide |
NZ591725A (en) | 2008-10-13 | 2012-09-28 | Cipla Ltd | PROCESS FOR THE PREPARATION OF RUFINAMIDE which is also known as 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide |
CN101768124B (zh) * | 2008-12-30 | 2012-01-04 | 北京本草天源药物研究院 | 一种药物晶体及其制备方法和用途 |
IT1395736B1 (it) * | 2009-08-04 | 2012-10-19 | Dipharma Francis Srl | Forme cristalline di rufinamide |
WO2011028288A1 (en) * | 2009-09-04 | 2011-03-10 | Tactical Therapeutics, Inc | Novel compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazole orotate formulations |
EP2465853A1 (en) * | 2010-12-14 | 2012-06-20 | Laboratorios Lesvi, S.L. | Polymorph of rufinamide and process for obtaining it |
WO2011135105A1 (en) * | 2010-04-30 | 2011-11-03 | Laboratorios Lesvi, S.L. | Improved process for preparing rufinamide intermediate |
ITMI20110718A1 (it) * | 2011-04-29 | 2012-10-30 | Dipharma Francis Srl | Procedimento per la purificazione di rufinamide |
US10206874B2 (en) | 2012-07-20 | 2019-02-19 | Hetero Research Foundation | Rufinamide solid dispersion |
WO2021099481A1 (en) | 2019-11-20 | 2021-05-27 | Medichem, S.A. | Solid composition containing rufinamide |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4346097A (en) * | 1980-09-30 | 1982-08-24 | Warner-Lambert Company | Method for treating convulsions with pyrazole-4-carboxamide derivatives |
US4511572A (en) * | 1983-03-18 | 1985-04-16 | The University Of Kentucky Research Foundation | Triazoline anticonvulsant drugs |
US4789680A (en) * | 1982-12-23 | 1988-12-06 | Ciba-Geigy Corporation | Aralkyltriazole compounds |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3992378A (en) | 1973-12-26 | 1976-11-16 | Eli Lilly And Company | Fluoralkyl quinoxadinediones |
US4156734A (en) * | 1976-02-13 | 1979-05-29 | Merck & Co., Inc. | Antihypertensive compositions containing an aryl-substituted alanine azo and an arylhydrazino-propionic acid |
GB1511195A (en) | 1976-10-18 | 1978-05-17 | Ici America Inc | Triazole derivatives |
US4536518A (en) * | 1979-11-01 | 1985-08-20 | Pfizer Inc. | Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine |
FI834666A (fi) | 1982-12-23 | 1984-06-24 | Ciba Geigy Ag | Foerfarande foer framstaellning av nya aralkyltriazolfoereningar. |
PH22568A (en) * | 1985-04-18 | 1988-10-17 | Ciba Geigy Ag | Fluorinated benzyl triazoles and pharmaceutical compositions containing the same |
CA2002864C (en) | 1988-11-29 | 1999-11-16 | Eddy J. E. Freyne | (1h-azol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives |
JPH02214504A (ja) | 1989-02-15 | 1990-08-27 | Nissan Chem Ind Ltd | 光学活性キノキサリン化合物の晶析法 |
JPH04506967A (ja) | 1989-07-27 | 1992-12-03 | ジー.ディー.サール アンド カンパニー | 高血圧症治療用腎選択性生成物 |
IL96507A0 (en) | 1989-12-08 | 1991-08-16 | Merck & Co Inc | Nitrogen-containing spirocycles and pharmaceutical compositions containing them |
DE69132340T2 (de) | 1990-11-06 | 2001-02-08 | Yamanouchi Pharma Co Ltd | Kondensiertes pyrazinderivat |
JP2753911B2 (ja) | 1991-12-06 | 1998-05-20 | キッセイ薬品工業株式会社 | N−tert−ブチル−1−メチル−3,3−ジフェニルプロピルアミン塩酸塩の結晶多形およびその製造方法 |
DE4217952A1 (de) | 1992-05-30 | 1993-12-02 | Basf Ag | Chinoxalin-2,3(1H,4H)-dione |
US5248699A (en) * | 1992-08-13 | 1993-09-28 | Pfizer Inc. | Sertraline polymorph |
US5631373A (en) | 1993-11-05 | 1997-05-20 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon | Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones |
GB9418443D0 (en) | 1994-09-13 | 1994-11-02 | Pfizer Ltd | Therapeutic agents |
GB9419318D0 (en) | 1994-09-24 | 1994-11-09 | Pfizer Ltd | Therapeutic agents |
BR9607295A (pt) | 1995-02-22 | 1997-11-25 | Hoechst Japan | Piretanida amorfa polimorfos de piretanida processo para a sua preparação e seu uso |
DE69712342T2 (de) * | 1996-07-11 | 2002-11-14 | Novartis Ag | Verfahren zur herstellung von 1-substituierten 4-cyan-1,2,3-triazolen |
TW526195B (en) * | 1997-06-10 | 2003-04-01 | Novartis Ag | Crystal modifications of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and their use |
-
1998
- 1998-06-04 TW TW087108858A patent/TW526195B/zh not_active IP Right Cessation
- 1998-06-04 TW TW087108859A patent/TW403740B/zh not_active IP Right Cessation
- 1998-06-08 PL PL330798A patent/PL192114B1/pl unknown
- 1998-06-08 WO PCT/EP1998/003427 patent/WO1998056772A1/en active IP Right Grant
- 1998-06-08 PT PT98934930T patent/PT994864E/pt unknown
- 1998-06-08 AT AT98934930T patent/ATE237599T1/de active
- 1998-06-08 HU HU0002113A patent/HU225153B1/hu unknown
- 1998-06-08 CA CA002256013A patent/CA2256013C/en not_active Expired - Lifetime
- 1998-06-08 CZ CZ19982534A patent/CZ292260B6/cs not_active IP Right Cessation
- 1998-06-08 EP EP98934930A patent/EP0994864B1/en not_active Expired - Lifetime
- 1998-06-08 CA CA2614926A patent/CA2614926C/en not_active Expired - Lifetime
- 1998-06-08 PE PE1998000479A patent/PE80999A1/es not_active IP Right Cessation
- 1998-06-08 HU HU0000798A patent/HU226107B1/hu unknown
- 1998-06-08 SK SK1093-98A patent/SK283685B6/sk not_active IP Right Cessation
- 1998-06-08 DE DE69811500T patent/DE69811500T2/de not_active Expired - Lifetime
- 1998-06-08 PL PL330764A patent/PL191943B1/pl unknown
- 1998-06-08 DK DK98934930T patent/DK0994864T3/da active
- 1998-06-08 JP JP53628898A patent/JP3672574B2/ja not_active Expired - Lifetime
- 1998-06-08 SI SI9830405T patent/SI0994863T1/xx unknown
- 1998-06-08 RU RU99104299/04A patent/RU2194041C2/ru active
- 1998-06-08 ES ES98934929T patent/ES2192779T3/es not_active Expired - Lifetime
- 1998-06-08 EP EP98934929A patent/EP0994863B1/en not_active Expired - Lifetime
- 1998-06-08 KR KR10-1998-0708150A patent/KR100425656B1/ko not_active IP Right Cessation
- 1998-06-08 AU AU84371/98A patent/AU725528B2/en not_active Expired
- 1998-06-08 PE PE1998000478A patent/PE79799A1/es not_active IP Right Cessation
- 1998-06-08 IL IL12573298A patent/IL125732A/en not_active IP Right Cessation
- 1998-06-08 ES ES98934930T patent/ES2197485T3/es not_active Expired - Lifetime
- 1998-06-08 BR BR9804946A patent/BR9804946A/pt not_active Application Discontinuation
- 1998-06-08 CA CA002256015A patent/CA2256015C/en not_active Expired - Lifetime
- 1998-06-08 AU AU84372/98A patent/AU725517B2/en not_active Expired
- 1998-06-08 TR TR1998/01631T patent/TR199801631T1/xx unknown
- 1998-06-08 TR TR1998/01630T patent/TR199801630T1/xx unknown
- 1998-06-08 WO PCT/EP1998/003428 patent/WO1998056773A1/en active IP Right Grant
- 1998-06-08 US US09/125,329 patent/US6740669B1/en not_active Expired - Lifetime
- 1998-06-08 CN CNB988056755A patent/CN1159300C/zh not_active Expired - Lifetime
- 1998-06-08 SI SI9830450T patent/SI0994864T1/xx unknown
- 1998-06-08 DK DK98934929T patent/DK0994863T3/da active
- 1998-06-08 KR KR10-1998-0708149A patent/KR100409168B1/ko not_active IP Right Cessation
- 1998-06-08 JP JP53628998A patent/JP3672575B2/ja not_active Expired - Lifetime
- 1998-06-08 DE DE122007000051C patent/DE122007000051I2/de active Active
- 1998-06-08 IL IL12573398A patent/IL125733A/en active Protection Beyond IP Right Term
- 1998-06-08 CN CN988000113A patent/CN1132820C/zh not_active Expired - Lifetime
- 1998-06-08 BR BR9804947A patent/BR9804947A/pt not_active Application Discontinuation
- 1998-06-08 ID IDW980066D patent/ID21014A/id unknown
- 1998-06-08 AT AT98934929T patent/ATE232852T1/de active
- 1998-06-08 DE DE69813560T patent/DE69813560T2/de not_active Expired - Lifetime
- 1998-06-08 ID IDW980065D patent/ID27660A/id unknown
- 1998-06-08 RU RU99104300/04A patent/RU2198167C2/ru active
- 1998-06-08 SK SK1094-98A patent/SK283734B6/sk not_active IP Right Cessation
- 1998-06-08 CZ CZ19982533A patent/CZ292481B6/cs not_active IP Right Cessation
- 1998-06-08 CN CNB2004100473675A patent/CN1298708C/zh not_active Expired - Lifetime
- 1998-06-08 NZ NZ331371A patent/NZ331371A/xx not_active IP Right Cessation
- 1998-06-08 NZ NZ331370A patent/NZ331370A/xx not_active IP Right Cessation
- 1998-06-09 MY MYPI98002572A patent/MY125854A/en unknown
- 1998-06-09 CO CO98032879A patent/CO4940452A1/es unknown
- 1998-06-09 ZA ZA984967A patent/ZA984967B/xx unknown
- 1998-06-09 ZA ZA984966A patent/ZA984966B/xx unknown
- 1998-06-09 AR ARP980102707A patent/AR012945A1/es not_active Application Discontinuation
- 1998-06-09 MY MYPI98002570A patent/MY120156A/en unknown
- 1998-06-09 CO CO98032885A patent/CO4940448A1/es unknown
- 1998-06-09 AR ARP980102708A patent/AR012946A1/es not_active Application Discontinuation
- 1998-08-11 NO NO19983667A patent/NO329315B1/no not_active IP Right Cessation
- 1998-08-11 NO NO19983666A patent/NO329314B1/no not_active IP Right Cessation
-
1999
- 1999-12-10 UY UY25844A patent/UY25844A1/es not_active Application Discontinuation
-
2000
- 2000-10-25 HK HK00106804A patent/HK1028241A1/xx not_active IP Right Cessation
- 2000-10-25 HK HK00106807A patent/HK1028242A1/xx not_active IP Right Cessation
- 2000-11-17 HK HK00107340A patent/HK1028031A1/xx not_active IP Right Cessation
-
2001
- 2001-05-31 US US09/871,366 patent/US6455556B2/en not_active Expired - Lifetime
-
2002
- 2002-11-14 US US10/294,408 patent/US20030125568A1/en not_active Abandoned
-
2004
- 2004-02-26 US US10/787,528 patent/US20040167186A1/en not_active Abandoned
-
2006
- 2006-01-11 US US11/329,945 patent/US7750028B2/en not_active Expired - Fee Related
-
2007
- 2007-05-17 AR ARP070102132A patent/AR061005A2/es not_active Application Discontinuation
- 2007-05-17 AR ARP070102131A patent/AR061004A2/es unknown
- 2007-07-03 NL NL300284C patent/NL300284I2/nl unknown
- 2007-07-04 LU LU91345C patent/LU91345I2/fr unknown
- 2007-07-06 FR FR07C0037C patent/FR07C0037I2/fr active Active
- 2007-07-13 CY CY200700014C patent/CY2007014I2/el unknown
-
2010
- 2010-04-26 US US12/767,003 patent/US8076362B2/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4346097A (en) * | 1980-09-30 | 1982-08-24 | Warner-Lambert Company | Method for treating convulsions with pyrazole-4-carboxamide derivatives |
US4789680A (en) * | 1982-12-23 | 1988-12-06 | Ciba-Geigy Corporation | Aralkyltriazole compounds |
US4511572A (en) * | 1983-03-18 | 1985-04-16 | The University Of Kentucky Research Foundation | Triazoline anticonvulsant drugs |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1298708C (zh) | 1-(2,6-二氟苄基)-1h-1,2,3-三唑-4-甲酰胺的结晶改良体及其用途 | |
CN1125067C (zh) | 结晶抗真菌多晶型物 | |
EP0407342A2 (de) | Neue Pyrimidin Derivate | |
BG98248A (bg) | Хинуклидинови производни | |
EP0415886A2 (de) | Aza-Verbindungen | |
CN105769792A (zh) | 含1-(β-D-吡喃葡糖基)-3-(苯基噻吩基甲基)苯化合物的片剂 | |
CN1149994C (zh) | 左西孟旦口服组合物 | |
CA1339803C (en) | Dideoxydidehydrocarbocyclic nucleosides | |
JPS601161A (ja) | N−ホルミル、n−ヒドロキシメチル−3−フエノキシ−1−アゼチジンカルボキサミド、その製造方法及びそれからなる鎮痙剤 | |
JPS58225086A (ja) | 放射線治療または化学療法に有用な化合物 | |
FR2580642A1 (fr) | 5-pyrimidinecarboxamides et traitement de la leucemie et des tumeurs en les utilisant | |
CN112812099B (zh) | 一种用于治疗消化性溃疡的化合物及其制法和用途 | |
CN85108245A (zh) | 新晶型苯并噻嗪二氧化物盐的制备方法 | |
CN1058020A (zh) | 诺贝拉斯丁柠檬酸盐 | |
DE3314196A1 (de) | Heterocyclylaether | |
CN1136201C (zh) | 药理活性的对映体及其制备方法 | |
JPH0925268A (ja) | 2−ニトロイミダゾール誘導体 | |
JP3338600B2 (ja) | 新規ジフェニルプロピルピペラジン誘導体 | |
WO2024066984A1 (zh) | 三并环类衍生物、药物组合物以及应用 | |
CN113979931A (zh) | 一种吡啶3-胺衍生物及其制备方法和应用 | |
US20050119275A1 (en) | Salt and crystal forms of (5-chloro-2-{2-[4-(4-fluoro-benzyl)-(2R,5S)-2,5-dimethyl-piperazin-1-yl]-2-oxo-ethoxy}-phenyl)-methanesulfonic acid | |
CN116710460A (zh) | 联苯衍生物及其应用 | |
JPS58206592A (ja) | トリフルオロメチルスピロ〔イミダゾリジン−4,3′−インドリン〕−2,2′,5−トリオン、その製法および該化合物を含有する糖尿病またはガラクト−ス血症の合併症の治療または予防に使用するための製薬組成 | |
JPS62278999A (ja) | 新規リゾチ−ム活性測定基質 | |
JPWO2004024143A1 (ja) | 医薬組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: NOVARTIS CO., LTD. Free format text: FORMER NAME: NOVARTIS AG |
|
CP01 | Change in the name or title of a patent holder |
Address after: Basel Patentee after: Novartis Ag Address before: Basel Patentee before: Novartis AG |
|
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20070207 |